Ken Herrmann1, Christina Bluemel2, Martina Weineisen3, Margret Schottelius3, Hans-Jürgen Wester4, Johannes Czernin5, Uta Eberlein2, Seval Beykan2, Constantin Lapa2, Hubertus Riedmiller6, Markus Krebs6, Saskia Kropf7, Andreas Schirbel2, Andreas K Buck2, Michael Lassmann2. 1. Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, Los Angeles, California Herrmann_K1@ukw.de. 2. Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. 3. Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany. 4. Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany Scintomics GmbH, Fürstenfeldbruck, Germany; and. 5. Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, Los Angeles, California. 6. Department of Urology, University Hospital Würzburg, Würzburg, Germany. 7. Scintomics GmbH, Fürstenfeldbruck, Germany; and.
Abstract
UNLABELLED: Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and treatment of prostate cancer. EuK-Subkff-(68)Ga-DOTAGA ((68)Ga-PSMA Imaging & Therapy [PSMA I&T]) is a recently introduced PET tracer for imaging PSMA expression in vivo. Whole-body distribution and radiation dosimetry of this new probe were evaluated. METHODS: Five patients with a history of prostate cancer were injected intravenously with 91-148 MBq of (68)Ga-PSMA I&T (mean ± SD, 128 ± 23 MBq). After an initial series of rapid whole-body scans, 3 static whole-body scans were acquired at 1, 2, and 4 h after tracer injection. Time-dependent changes of the injected activity per organ were determined. Mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM. RESULTS: Injection of 150 MBq of (68)Ga-PSMA I&T resulted in an effective dose of 3.0 mSv. The kidneys were the critical organ (33 mGy), followed by the urinary bladder wall and spleen (10 mGy each), salivary glands (9 mGy each), and liver (7 mGy). CONCLUSION: (68)Ga-PSMA I&T exhibits a favorable dosimetry, delivering organ doses that are comparable to (kidneys) or lower than those delivered by (18)F-FDG.
UNLABELLED: Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and treatment of prostate cancer. EuK-Subkff-(68)Ga-DOTAGA ((68)Ga-PSMA Imaging & Therapy [PSMA I&T]) is a recently introduced PET tracer for imaging PSMA expression in vivo. Whole-body distribution and radiation dosimetry of this new probe were evaluated. METHODS: Five patients with a history of prostate cancer were injected intravenously with 91-148 MBq of (68)Ga-PSMA I&T (mean ± SD, 128 ± 23 MBq). After an initial series of rapid whole-body scans, 3 static whole-body scans were acquired at 1, 2, and 4 h after tracer injection. Time-dependent changes of the injected activity per organ were determined. Mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM. RESULTS: Injection of 150 MBq of (68)Ga-PSMA I&T resulted in an effective dose of 3.0 mSv. The kidneys were the critical organ (33 mGy), followed by the urinary bladder wall and spleen (10 mGy each), salivary glands (9 mGy each), and liver (7 mGy). CONCLUSION: (68)Ga-PSMA I&T exhibits a favorable dosimetry, delivering organ doses that are comparable to (kidneys) or lower than those delivered by (18)F-FDG.
Authors: Christian Uprimny; Alexander Kroiss; Bernhard Nilica; Sabine Buxbaum; Clemens Decristoforo; Wolfgang Horninger; Irene J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2014-10-08 Impact factor: 9.236
Authors: Ludovic Ferrer; Françoise Kraeber-Bodéré; Caroline Bodet-Milin; Caroline Rousseau; Stephen Le Gouill; William A Wegener; David M Goldenberg; Manuel Bardiès Journal: Cancer Date: 2010-02-15 Impact factor: 6.860
Authors: Flavio Forrer; Eric P Krenning; Peter P Kooij; Bert F Bernard; Mark Konijnenberg; Willem H Bakker; Jaap J M Teunissen; Marion de Jong; Kirsten van Lom; Wouter W de Herder; Dik J Kwekkeboom Journal: Eur J Nucl Med Mol Imaging Date: 2009-02-27 Impact factor: 9.236
Authors: Jeffrey S Ross; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Iain Webb; Gary S Gray; Rebecca Mosher; Bhaskar V S Kallakury Journal: Clin Cancer Res Date: 2003-12-15 Impact factor: 12.531
Authors: Uta Eberlein; Jörn Hendrik Bröer; Charlot Vandevoorde; Paula Santos; Manuel Bardiès; Klaus Bacher; Dietmar Nosske; Michael Lassmann Journal: Eur J Nucl Med Mol Imaging Date: 2011-08-30 Impact factor: 9.236
Authors: A Pfestroff; M Luster; C A Jilg; P J Olbert; C H Ohlmann; M Lassmann; H R Maecke; S Ezziddin; L Bodei Journal: Eur J Nucl Med Mol Imaging Date: 2015-12 Impact factor: 9.236
Authors: Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2017-06 Impact factor: 9.236
Authors: Sangeeta Ray Banerjee; Zhengping Chen; Mrudula Pullambhatla; Ala Lisok; Jian Chen; Ronnie C Mease; Martin G Pomper Journal: Bioconjug Chem Date: 2016-05-09 Impact factor: 4.774
Authors: Kambiz Rahbar; Ali Afshar-Oromieh; Martin Bögemann; Stefan Wagner; Michael Schäfers; Lars Stegger; Matthias Weckesser Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-14 Impact factor: 9.236
Authors: Sebastian Schmuck; Stefan Nordlohne; Christoph-A von Klot; Christoph Henkenberens; Jan M Sohns; Hans Christiansen; Hans-Jürgen Wester; Tobias L Ross; Frank M Bengel; Thorsten Derlin Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-09 Impact factor: 9.236
Authors: Constantinos Zamboglou; Gesche Wieser; Steffen Hennies; Irene Rempel; Simon Kirste; Martin Soschynski; Hans Christian Rischke; Tobias Fechter; Cordula A Jilg; Mathias Langer; Philipp T Meyer; Michael Bock; Anca-Ligia Grosu Journal: Eur J Nucl Med Mol Imaging Date: 2015-11-23 Impact factor: 9.236